DWA
ALDX icon

Dorsey Wright & Associates’s Aldeyra Therapeutics ALDX Stock Holding History

Dorsey Wright & Associates’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,223
Closed -$32K – 285
2023
Q1 		$32K Sell
3,223
-357
-10% -$2.52K 0.01% 151
2022
Q4 		$24.9K Buy
+3,580
New +$20.5K 0.01% 215
2020
Q4 		– Sell
-1,234
Closed -$9K – 306
2020
Q3 		$9K Buy
+1,234
New +$7.97K ﹤0.01% 205
2019
Q2 		– Sell
-800
Closed -$7K – 282
2019
Q1 		$7K Buy
+800
New +$6.8K ﹤0.01% 249

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Dorsey Wright & Associates's ALDX Position: Q2 2023 in Review

Dorsey Wright & Associates sold out of Aldeyra Therapeutics (ALDX) in Q2 2023, closing a stake of 3,223 shares — an estimated $32K sold.

Dorsey Wright & Associates first reported a position in ALDX in Q1 2019 and held it in 4 quarters. The position peaked at $32K in Q1 2023. 119 funds tracked by Wall St. Rank hold ALDX as of Q2 2023.

  • Dorsey Wright & Associates reported no remaining Aldeyra Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Dorsey Wright & Associates sold 3,223 Aldeyra Therapeutics shares in Q2 2023, an estimated $32K.
  • Dorsey Wright & Associates first reported a position in Aldeyra Therapeutics in Q1 2019 and held it in 4 quarters.
  • Dorsey Wright & Associates's Aldeyra Therapeutics position peaked at $32K in Q1 2023.
  • 119 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2023.

Based on Dorsey Wright & Associates's 13F filing for Q2 2023, filed 26 Jul 2023.